^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    conteltinib (SY-707)

    i
    Other names: SY-707, CT 707, CT-707
    Company:
    Centaurus Biopharma, Shouyao Holdings
    Drug class:
    ALK inhibitor, Multi-tyrosine kinase inhibitor, IGF-1R inhibitor, FAK inhibitor, Pyk2 inhibitor
    Related drugs:
    7ms
    Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation (clinicaltrials.gov)
    P1/2, N=102, Not yet recruiting, Shouyao Holdings (Beijing) Co. LTD
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12
    |
    conteltinib (SY-707) • SY-5933
    3years
    Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study. (PubMed, BMC Med)
    In this study, conteltinib showed manageable safety profile, favorable PK properties, and anti-tumor activity in advanced ALK-positive NSCLC patients. The recommended phase 2 dose was determined to be 600 mg QD for ALK TKI-naïve patients and 300 mg bis in die (BID) for patients who received crizotinib previously.
    P1 data • Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Xalkori (crizotinib) • conteltinib (SY-707)